117490-57-0

Usage

Uses

Used in Pharmaceutical Industry:
4-(benzyloxy)-2-chlorobenzaldehyde is utilized as a key intermediate in the synthesis of various pharmaceuticals, contributing to the development of new drugs due to its unique chemical properties and reactivity.
Used in Agrochemical Industry:
In the agrochemical sector, 4-(benzyloxy)-2-chlorobenzaldehyde serves as an essential intermediate for the production of different agrochemicals, playing a role in the creation of compounds that can enhance crop protection and yield.
Used in Organic Chemistry:
4-(benzyloxy)-2-chlorobenzaldehyde is employed as a versatile building block in organic chemistry for the synthesis of a range of organic compounds, leveraging its distinct structural features and reactivity in various chemical reactions.

Upstream product

• 56962-11-9 2-chloro-4-hydroxybenzaldehyde 
• 100-39-0 benzyl bromide 
• 100-44-7 benzyl chloride 
• 3336-16-1 2-chloro-4-hydroxybenzonitrile 
• 100-51-6 benzyl alcohol 
• 84194-36-5 2-chloro-4-fluorobenzaldehyde 
• 2420-16-8 4-hydroxy-3-chlorobenzaldehyde 
• 853953-30-7 2-chloro-4-benzyloxybenzonitrile 

Downstream Products

• 117490-58-1 8-benzyloxy-7,8-didemethyl-5-deazariboflavin 
• 67759-10-8 1-[4-(benzyloxy)-2-chlorophenyl]-2-(tert-butylamino)ethanol 
• 58020-43-2 (-)-α-[(tert-Butylamino)methyl]-2-chloro-4-hydroxybenzyl alcohol 
• 1048041-45-7 C₄₀H₅₁ClN₂O₇SSi 
• 1048041-27-5 2-[11-(4-(benzyloxy)-2-chlorophenyl)-6-hydroxy-3,3-dimethyl-1-oxo-1,2,3,4,5,11-hexahydrodibenzo[b,e][1,4]diazepine-10-sulfonyl]-N-(1H-tetrazol-5-yl)acetamide 
• 1048041-24-2 N-((11-(4-(benzyloxy)-2-chlorophenyl)-6-hydroxy-3,3-dimethyl-1-oxo-1,2,3,4,5,11-hexahydrodibenzo[b,e][1,4]diazepin-10-yl)sulfonyl)acetylmethanesulfonamide 
• 1048041-28-6 3-[11-(4-(benzyloxy)-2-chlorophenyl)-6-hydroxy-3,3-dimethyl-1-oxo-1,2,3,4,5,11-hexahydrodibenzo[b,e][1,4]diazepine-10-sulfonyl]propionic acid methyl ester 
• 1048041-26-4 2-[11-(4-(benzyloxy)-2-chlorophenyl)-6-hydroxy-3,3-dimethyl-1-oxo-1,2,3,4,5,11-hexahydrodibenzo[b,e][1,4]diazepine-10-sulfonyl]acetamide 
• 1048041-23-1 C₃₁H₃₁ClN₂O₇S 
• 1048041-25-3 [11-(4-(benzyloxy)-2-chlorophenyl)-6-hydroxy-3,3-dimethyl-1-oxo-1,2,3,4,5,11-hexahydrodibenzo[b,e][1,4]diazepine-10-sulfonyl]acetic acid 
• 1048041-29-7 11-(4-benzyloxy-2-chlorophenyl)-6-hydroxy-10-methanesulfonyl-3,3-dimethyl-2,3,4,5,10,11-hexahydrodibenzo[b,e][1,4]diazepin-1-one 
• 1048041-44-6 C₃₇H₄₇ClN₂O₃Si 
• 178053-33-3 4-chloro-1-methyl-6-(4-nitrophenoxy)-2-indoloylguanidine 
• 178053-29-7 4-chloro-1-methyl-6-(2-nitrophenoxy)-2-indoloylguanidine 

Relevant academic research and scientific papers

Synthesis of the β2-Agonist Tulobuterol and Its Metabolite 4-Hydroxytulobuterol

Abstract: Alternative methods have been developed for the synthesis of theβ2-agonist tulobuterol and its metabolite4-hydroxytulobuterol with a similar activity. The proposed procedures utilizeavailable reagents, and the key stage in the synthesis is the formation ofintermediate oxirane according to the Corey–Chaykovsky reaction, followed byopening of the oxirane ring by the action of excess tert-butylamine. In the synthesis of 4-hydroxytulobuterol, thehydroxy group was protected by benzylation, and the protecting group was removedin the final stage by hydrogenation over carbon-supported palladium.

THIOARYL DERIVATIVES AS GPR120 AGONISTS

The present invention relates to thioaryl derivatives of Formula 1 as defined in the specification, a method for preparing the same, a pharmaceutical composition comprising the same and use thereof. The thioaryl derivatives of Formula 1 according to the present invention promote GLP-1 formation in the gastrointestinal tract and improve insulin resistance in macrophages, pancreas cells, etc. due to anti-inflammatory action, and can accordingly be effectively used for preventing or treating diabetes, complications of diabetes, inflammation, obesity, non-alcoholic fatty liver, steatohepatitis or osteoporosis.

Control of the intracellular levels of prostaglandin E2 through inhibition of the 15-hydroxyprostaglandin dehydrogenase for wound healing

Excessive scar formation is an aberrant form of wound healing and is an indication of an exaggerated function of fibroblasts and excess accumulation of extracellular matrix during wound healing. Much experimental data suggests that prostaglandin E2 (PGE2) plays a role in the prevention of excessive scarring. However, it has a very short half-live in blood, its oxidization to 15-ketoprostaglandins is catalyzed by 15-hydroxyprostaglandin dehydrogenase (15-PGDH). Previously, we reported that 15-PGDH inhibitors significantly increased PGE2 levels in A549 cells. In our continuing attempts to develop highly potent 15-PGDH inhibitors, we newly synthesized various thiazolidine-2,4-dione derivatives. Compound 27, 28, 29, and 30 demonstrated IC50 values of 0.048, 0.020, 0.038 and 0.048 μM, respectively. They also increased levels of PGE2 in A549 cells. Especially, compound 28 significantly increased level of PGE2 at 260 pg/mL, which was approximately fivefold higher than that of control. Scratch wounds were analyzed in confluent monolayers of HaCaT cells. Cells exposed to compound 28 showed significantly improved wound healing with respect to control.

NOVEL THIAZOLIDINEDIONE DERIVATIVE AND USE THEREOF

The present invention relates to novel thiazolidinedione derivatives expressed by the following formula (I) and the uses thereof. More specifically, the present invention relates to novel thiazolidinedione derivatives expressed by the following formula (I) and a pharmaceutical composition comprising the same. The novel thiazolidinedione derivatives of formula (I) according to the present invention can be effectively used for the prevention or treatment of cardiovascular disease, gastrointestinal disease and renal disease by inhibiting the activity of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) that decomposes prostaglandins as well as useful for the prevention of hair loss and the stimulation of hair growth, and osteogenic stimulation and wound healing.

SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME

Provided are a substituted azole derivative and pharmaceutically acceptable salts thereof, a pharmaceutical composition including an effective amount of the derivative, and a method for treating Parkinson's disease in a mammal including administering an e

6-HYDROXY-DIBENZODIAZEPINONES USEFUL AS HEPATITIS C VIRUS INHIBITORS

Inhibitors of HCV replication of formula (I) the stereoisomers, prodrugs, tautomers, racemics, salts, hydrates or solvates thereof wherein R1, R2; R3; R4a and R4b have the meaning defined in the claims.The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use in HCV therapy.

10-SULFONYL-DIBENZODIAZEPINONES USEFUL AS HEPATITIS C VIRUS INHIBITORS

Inhibitors of HCV replication of formula (I) and the stereoisomers, prodrugs, tautomers, racemics, salts, hydrates or solvates thereof, wherein X, Y, R1; R2; R3; R4a and R4b have the meaning defined in the claims. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use in HCV therapy.

Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors

A compound of formula (I), or a pharmaceutically acceptable salt and/or solvate (including hydrate) thereof; and the use of a compound of formula (I) in the treatment of a TNF-mediated disease, disorder, or condition, or a p38-mediated disease, disorder, or condition, in particular the allergic and non-allergic airways diseases, more particularly obstructive or inflammatory airways diseases, preferably chronic obstructive pulmonary disease.

First total synthesis of coenzyme factor 420

The first total synthesis of Methanobacterium redox coenzyme Factor 420 (F420) has been achieved by the formation of a phosphotriester bond between a protected 8-hydroxy-10-D-ribityl-5-deazaisoalloxazine moiety and a peptide moiety, (L-lactoyl-γ-L-glutamyl)-L-glutamic acid tribenzyl ester, by the phosphite triester approach using 2,2,2-trichloroethyl phosphorodichloridite, followed by successive deprotection procedures.